# Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

> **NCT01009515** · PHASE2 · TERMINATED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 19 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Paclitaxel, carboplatin, temozolomide

## Key facts

- **NCT ID:** NCT01009515
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2013-09
- **Final completion:** 2015-06
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Low accrual; target accrual not met
- **Last updated:** 2017-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009515, "Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01009515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*